Findings

What do systematic reviews say?

19 questions · 19 findings · 7 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 47.4%GRADE not reported 0 · 0%Very low 2 · 10.5%Low 4 · 21.1%Moderate 4 · 21.1%High 0 · 0%

Oral creatine vs placebo

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Oral olesoxime vs placebo

Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
Low

Oral gabapentin vs placebo

Change in quality of life · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low

Oral hydroxyurea vs placebo

Change in quality of life · children and adults with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid vs placebo

Change in quality of life · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
28 participants
Moderate

Oral phenylbutyrate vs placebo

Change in quality of life · children with SMA type II

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in quality of life · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Oral azithromycin vs placebo

QoL · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 177 participants
Moderate

Oral antibiotics vs placebo

Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis

1 finding from 1 review

Interventions to reduce Staphylococcus aureus in the management of eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Moderate

Summary of findings: oral antioxidants (NAC/GSH) vs placebo

Quality of life: change from baseline in CFQ‐R · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Summary of findings: oral antioxidant combination vs control

Quality of life: Quality of Well Being score change from baseline · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: oral antioxidant combination vs control

Quality of life: Quality of Well Being score change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

Secondary outcome: quality of life · adults with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Loratadine 10 mg vs placebo (4‐week intervention)

Secondary outcome: quality of life · adults with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Loratadine 10 mg vs placebo (2‐week intervention)

Secondary outcome: quality of life · adults with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Secondary outcome: quality of life · children with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cetirizine 10 mg/d vs placebo (4‐week intervention)

Secondary outcome: quality of life · adults with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticholinergic medication vs placebo

Disease‐specific quality of life · Adults with overactive bladder (OAB)

Anticholinergics showed no clear difference in mean change from baseline in condition‐specific quality of lifeScale… compared with placebo (low certainty).

1 finding from 1 review

Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults 2023 · Cochrane Headline outcomes only
MD 4.41
12 studies · 6804 participants
Low